Way too early to draw any conclusions on latest press release about experimental oral Covid-19 treatment based on unpublished mid-study secondary endpoints for molnupiravir.

Dr. Barry Dworkin

Medical Mythbusting Commentary for March 8, 2021

Way too early to draw any conclusions on latest press release about experimental oral Covid-19 treatment based on unpublished mid-study secondary endpoints for molnupiravir. Play Now | Play in Popup | Download

Source:
Covid-19 Pill Shows Promise in Preliminary Testing

Related posts:

  1. Dairy study results have more holes than Swiss cheese. It is the trifecta of being a press release, unpublished, and an observational study. Nothing to see here.
  2. Unpublished, uncontrolled small study claims that experimental exosome treatment shortens recovery time to five days for patients with severe Covid-19. Further human trials required to prove it truly works.
  3. Alzheimer drug press release requires further scrutiny
  4. It is too soon to draw any conclusions about short/long term immunity based on COVID-19 antibody levels. Many unknown factors remain. Time should help with the answers in future studies.
Bitnami